Entrar Registro gratuito

Last updated: 8 June 2023 at 4:39pm EST

Thomas Soloway Net Worth



Mr. Soloway STSA stock SEC Form 4 insiders trading

Thomas has made over 2 trades of the Satsuma Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 150,888 units of STSA stock worth $494,913 on 8 January 2020.

The largest trade he's ever made was exercising 150,888 units of Satsuma Pharmaceuticals stock on 8 January 2020 worth over $494,913. On average, Thomas trades about 14,785 units every 2 days since 2017. As of 8 January 2020 he still owns at least 183,384 units of Satsuma Pharmaceuticals stock.

You can see the complete history of Mr. Soloway stock trades at the bottom of the page.





Thomas Soloway biography

Thomas P. Soloway serves as Director of the Company. Mr. Soloway currently serves as Executive Vice President and Chief Operating Officer at Audentes Therapeutics, Inc., a biotechnology company acquired by Astellas Pharma Inc. in January 2020. Mr. Soloway joined Audentes as its Senior Vice President and Chief Financial Officer in October 2015. Prior to joining Audentes, Mr. Soloway served as the Senior Vice President and Chief Financial Officer of Ascendis Pharma A/S from January 2014 until September 2015. Prior to Ascendis, Mr. Soloway co-founded Transcept Pharmaceuticals, Inc., a biotechnology company, in 2002. At Transcept, Mr. Soloway held various positions, including Chief Financial Officer and Executive Vice President, Chief Operating Officer. Prior to joining Transcept, Mr. Soloway financed and advised early stage healthcare and life sciences companies as a Principal at Montreux Equity Partners. Mr. Soloway earned a B.S. in Entrepreneurial Studies from the University of Southern California and an M.B.A. from Georgetown University.



How old is Thomas Soloway?

Thomas Soloway is 53, he's been the Director of Satsuma Pharmaceuticals since 2020. There are 12 older and 3 younger executives at Satsuma Pharmaceuticals. The oldest executive at Satsuma Pharmaceuticals, Inc. is Alan C. Mendelson J.D., 71, who is the Sec..

Insiders trading at Satsuma Pharmaceuticals

Over the last 5 years, insiders at Satsuma Pharmaceuticals have traded over $2,307,500 worth of Satsuma Pharmaceuticals stock and bought 63,855,812 units worth $106,923,937 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Capital Management, L.P.Ra ..., eNippon Biomedical Laborator.... On average, Satsuma Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $2,050,940. The most recent stock trade was executed by Ken Takanashi on 6 June 2023, trading 22,053,581 units of STSA stock currently worth $20,068,759.



What does Satsuma Pharmaceuticals do?

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.



What does Satsuma Pharmaceuticals's logo look like?

Satsuma Pharmaceuticals, Inc. logo

Satsuma Pharmaceuticals executives and stock owners

Satsuma Pharmaceuticals executives and other stock owners filed with the SEC include: